Monthly PCSK9 inhibitors: The CHOICE for prolonged duration of effect

被引：1
|
作者：
de Carvalho, Luiz Sergio F. [1 ]
Yoshida, Hiroshi [2 ]
机构：
[1] State Univ Campinas Unicamp, Dept Cardiol, Campinas, SP, Brazil
[2] Jikei Univ, Kashiwa Hosp, Dept Lab Med, Chiba, Japan
来源：
ATHEROSCLEROSIS | 2016年 / 254卷
关键词：
PCSK9; inhibitors; Lipid modifying drugs; Hypercholesterolemia; Clinical trials; SUBTILISIN/KEXIN TYPE 9; EVOLOCUMAB AMG 145; HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA; DENSITY-LIPOPROTEIN CHOLESTEROL; STATIN-INTOLERANT PATIENTS; HUMAN MONOCLONAL-ANTIBODY; RANDOMIZED-TRIAL; SAFETY; EFFICACY; METAANALYSIS;
D O I：
10.1016/j.atherosclerosis.2016.09.013
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：300 / 302
页数：3
相关论文
共 50 条
  • [1] Monoclonal antibodies targeting PCSK9 and the search for prolonged duration of effect
    Ridker, Paul M.
    EUROPEAN HEART JOURNAL, 2016, 37 (17) : 1370 - 1372
  • [2] PCSK9 inhibitors
    Farnier, Michel
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2015, 19 (03): : 66 - 70
  • [3] PCSK9 inhibitors
    Farnier, Michel
    CURRENT OPINION IN LIPIDOLOGY, 2013, 24 (03) : 251 - 258
  • [4] PCSK9 inhibitors
    Gencer, Baris
    Lambert, Gilles
    Mach, Francois
    SWISS MEDICAL WEEKLY, 2015, 145
  • [5] No effect of PCSK9 inhibitors on cognitive function
    Irene Fernández-Ruiz
    Nature Reviews Cardiology, 2017, 14 : 568 - 568
  • [6] PCSK9 Inhibitors and the Choice Between Innovation, Efficiency, and Affordability
    Mark, Daniel B.
    Schulman, Kevin A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 318 (08): : 711 - 712
  • [7] SIDE EFFECT PROFILE IN PCSK9 INHIBITORS
    Collins, Matthew
    Weber, Benjamin
    Dajani, Khaled
    CLINICAL CARDIOLOGY, 2019, 42 : S44 - S45
  • [8] Safety of PCSK9 inhibitors
    Grzesk, Grzegorz
    Dorota, Bednarska
    Wolowiec, Lukasz
    Wolowiec, Anna
    Osiak, Joanna
    Kozakiewicz, Mariusz
    Banach, Joanna
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 156
  • [9] Access to PCSK9 Inhibitors
    Baum, Seth J.
    Lepor, Norman E.
    Robinson, Jennifer G.
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2018, 19 : S47 - S50
  • [10] PCSK9 inhibitors are go
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2015, 14 (09) : 593 - 593
12345